SUPT6H controls estrogen receptor activity and cellular differentiation by multiple epigenomic mechanisms

Oncogene

Volumn 34, Issue 4, 2015, Pages 465-473

  Bedi, U ^a,b   Scheel, A H ^b,c   Hennion, M ^b   Begus Nahrmann, Y ^b   Ruschoff J ^c   Johnsen, S A ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c Institute of Pathology Nordhessen   (Germany)

Author keywords

breast cancer; chromatin; differentiation; Estrogen receptor

Indexed keywords

CHROMATIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; HISTONE; SUPT6H PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

BREAST TUMOR; CELL DIFFERENTIATION; CHEMISTRY; CHROMATIN; EPIGENETICS; FEMALE; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; UBIQUITINATION;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMATIN; EPIGENOMICS; ESTROGEN RECEPTOR ALPHA; FEMALE; HISTONES; HUMANS; TRANSCRIPTION FACTORS; UBIQUITINATION;

EID: 85028194690     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.558     Document Type: Article

References (46)

1. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest 2006; 116: 561-570.
2. Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence and significance. J Mammary Gland Biol Neoplasia 2000; 5: 271-281.
3. Khan SA, Rogers MAM, Khurana KK, Meguid MM, Numann PJ. Estrogen receptor expression in benign breast epithelium and breast cancer risk. JNCI J Natl Cancer Inst 1998; 90: 37-42.
4. Theodorou V, Stark R, Menon S, Carroll JS. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res 2013; 23: 12-22.
5. Kininis M, Isaacs GD, Core LJ, Hah N, Kraus WL. Postrecruitment regulation of RNA polymerase II directs rapid signaling responses at the promoters of estrogen target genes. Mol Cell Biol 2009; 29: 1123-1133.
6. Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene 2005; 24: 5576-5588.
7. Egloff S, Murphy S. Cracking the RNA polymerase II CTD code. Trends Genet 2008; 24: 280-288.
8. Ogba N, Chaplin LJ, Doughman YQ, Fujinaga K, Montano MM. HEXIM1 regulates 17b-estradiol/estrogen receptor-a-mediated expression of cyclin d1 in mammary cells via modulation of P-TEFb. Cancer Res 2008; 68: 7015-7024.
9. Ketchart W, Ogba N, Kresak A, Albert JM, Pink JJ, Montano MM. HEXIM1 is a critical determinant of the response to tamoxifen. Oncogene 2011; 30: 3563-3569.
10. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128: 693-705.
11. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128: 707-719.
12. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009; 462: 58-64.
13. Métivier R, Reid G, Gannon F. Transcription in four dimensions: nuclear receptordirected initiation of gene expression. EMBO Rep 2006; 7: 161-167.
14. Johnsen SA, Kangaspeska S, Reid G, Gannon F. Interfering with the dynamics of estrogen receptor-regulated transcription. Ernst Schering Found Symp Proc 2006; 1: 1-12.
15. Prenzel T, Begus-Nahrmann Y, Kramer F, Hennion M, Hsu C, Gorsler T et al. Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res 2011; 71: 5739-5753.
16. Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N et al. The histone H2Bspecific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev 2008; 22: 2664-2676.
17. Johnsen SA. The enigmatic role of H2Bub1 in cancer. FEBS Lett 2012; 586: 1592-1601.
18. Karpiuk O, Najafova Z, Kramer F, Hennion M, Galonska C, König A et al. The histone H2B monoubiquitination regulatory pathway is required for differentiation of multipotent stem cells. Mol Cell 2012; 46: 705-713.
19. Fuchs G, Shema E, Vesterman R, Kotler E, Wolchinsky Z, Wilder S et al. RNF20 and USP44 regulate stem cell differentiation by modulating H2B monoubiquitylation. Mol Cell 2012; 46: 662-673.
20. Chen S, Li J, Wang D-L, Sun F-L. Histone H2B lysine 120 monoubiquitination is required for embryonic stem cell differentiation. Cell Res 2012; 22: 1402-1405.
21. Minsky N, Shema E, Field Y, Schuster M, Segal E, Oren M. Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nature Cell Biol 2008; 10: 483-488.
22. Pirngruber J, Shchebet A, Schreiber L, Shema E, Minsky N, Chapman RD et al. CDK9 directs H2B monoubiquitination and controls replication-dependent histone mRNA 30-end processing. EMBO Rep 2009; 10: 894-900.
23. Johnsen SA. CDK9 and H2B monoubiquitination: a well-choreographed dance. PLoS Genet 2012; 8: e1002860.
24. Zhang F, Yu X. WAC, a functional partner of RNF20/40, regulates histone H2B ubiquitination and gene transcription. Mol Cell 2011; 41: 384-397.
25. Yoh SM, Cho H, Pickle L, Evans RM, Jones KA. The Spt6 SH2 domain binds Ser2-P RNAPII to direct Iws1-dependent mRNA splicing and export. Genes Dev 2007; 21: 160-174.
26. Diebold M-L, Loeliger E, Koch M, Winston F, Cavarelli J, Romier C. Noncanonical tandem SH2 enables interaction of elongation factor Spt6 with RNA polymerase II. J Biol Chem 2010; 285: 38389-38398.
27. Baniahmad C, Nawaz Z, Baniahmad A, Gleeson MA, Tsai MJ, O'Malley BW. Enhancement of human estrogen receptor activity by SPT6: a potential coactivator. Mol Endocrinol 1995; 9: 34-43.
28. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J et al. Genome-wide analysis of estrogen receptor binding sites. Nat Genet 2006; 38: 1289-1297.
29. Bortvin A, Winston F. Evidence that Spt6p controls chromatin structure by a direct interaction with histones. Science 1996; 272: 1473-1476.
30. Kim J, Guermah M, McGinty RK, Lee J-S, Tang Z, Milne TA et al. RAD6-Mediated transcription-coupled H2B ubiquitylation directly stimulates H3K4 methylation in human cells. Cell 2009; 137: 459-471.
31. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-527.
32. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9: 121-132.
33. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
34. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey R, Robertson JF et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203: 661-671.
35. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H et al. Systematic bioinformatic analysis of expression levels of 17 330 human genes across 9783 samples from 175 types of healthy and pathological tissues. Genome Biol 2008; 9: R139.
36. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SIS et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotech 2002; 20: 592-596.
37. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006; 12: 1168-1174.
38. Raaphorst FM, CJLM Meijer, Fieret E, Blokzijl T, Mommers E, Buerger H et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 2003; 5: 481-488.
39. Reijm EA, Jansen MPHM, Ruigrok-Ritstier K, van Staveren IL, Look MP, van Gelder MEM et al. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat 2011; 125: 387-394.
40. Chen S, Ma J, Wu F, Xiong L-J, Ma H, Xu W et al. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev 2012; 26: 1364-1375.
41. Wang AH, Zare H, Mousavi K, Wang C, Moravec CE, Sirotkin HI et al. The histone chaperone Spt6 coordinates histone H3K27 demethylation and myogenesis. EMBO J 2013; 32: 1075-1086.
42. Pirngruber J, Shchebet A, Johnsen SA. Insights into the function of the human P-TEFb component CDK9 in the regulation of chromatin modifications and co-transcriptional mRNA processing. Cell Cycle 2009; 8: 3636-3642.
43. Pirngruber J, Johnsen SA. Induced G1 cell-cycle arrest controls replicationdependent histone mRNA 30 end processing through p21, NPAT and CDK9. Oncogene 2010; 29: 2853-2863.
44. Kari V, Shchebet A, Neumann H, Johnsen SA. The H2B ubiquitin ligase RNF40 cooperates with SUPT16H to induce dynamic changes in chromatin structure during DNA double-strand break repair. Cell Cycle 2011; 10: 3495-3504.
45. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 2012; 9: 671-675.
46. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23: 291-299